The utility of directly leveraging DC-mediated CD4 help is evidenced to some degree in stage 3 melanoma patients, a small fraction of whom were found to have detectable circulating tumor antigen-specific CD8 T cells after DC vaccination with both MHC-I- and II-restricted epitopes but not with MHC-I-restricted epitopes alone (32). Here, CD8A is linked to melanoma.